AtriCure Q2 net income turns to USD 8.96 million; revenue rises 12.8% to USD 153.6 million year over year
ATRC•Segment revenue performance
Pain management revenue climbed 27.8% to USD 27.1 million, while minimally invasive ablation fell 23.1% to USD 6 million.
Appendage management revenue rose 14.4% to USD 51.6 million; open ablation increased 12.1% to USD 40.9 million.
European product launch plans
AtriCure received EU MDR CE mark for AtriClip FLEX-Mini and AtriClip PRO-Mini in April; it expects to launch both in Europe later this year.
Q2 revenue and profitability improve
AtriCure posted Q2 revenue of USD 153.6 million, up 12.8% year over year, swinging to net income of USD 9 million.
Operating income turned positive at USD 9.7 million; gross margin widened 2.69 percentage points to 77.2%.
